Fig. 1.

Current approaches to neutralize SARS-CoV-2 spike protein and to prevent its binding to the cellular ACE2. a Cocktails of neutralizing antibodies against spike protein of SARS-CoV-2, peptide-based binders blocking SARS-CoV-2-RBD-ACE2 interface, small molecule inhibitors blocking the host cell proteases, and soluble recombinant human ACE2 are currently being under different stages of development against COVID-19. b Chan and colleagues engineered a stable soluble variant of ACE2 with enhanced binding affinity to the RBD of SARS-CoV-2 spike protein, sustained angiotensin-2 peptidase activity, and superior abilities to block SARS-CoV-2 infection in vitro. RBD receptor-binding domain. Created by Zuzanna Lukasik, MD